The phase I CHRYSALIS trial found that patients with non–small cell lung cancer who carry a MET exon 14 skipping mutation responded well to treatment with amivantamab. The overall response rate (ORR) to the bispecific antibody was 33%, and median progression-free survival was 6.7 months. Amivantamab also showed encouraging efficacy in the phase I/Ib CHRYSALIS-2 study, which tested the agent in combination with lazertinib. Among patients whose disease advanced despite treatment with osimertinib, the ORR was 33% and the median overall survival was 14.8 months.

You do not currently have access to this content.